Table 1

	Rituximab	Tocilizumab	Golimumab	Adalimumab	Abatacept	Etanercept

	n=40	n=42	n=24	n=42	n=35	n=39

DAS 28	4.3 vs 3.7	4.2 vs 2.8	4.1 vs 3.4	3.4 vs 2.8	4.3 vs 3.1	4.0 vs 2.8
	P 0.014	P<0.001	P 0.028	P 0.011	P<0.001	P 0.0015
HAQ	1.3 vs 1.1	1.0 vs 0.9	1.2 vs 1.0	1.7 vs 0.5	1.2 vs 1.0	1.1 vs 0.7
						P<0.001
Swollen Joint Count	3.8 vs 2.1	5.0 vs 1.8	5.3 vs 6.7	3.6 vs 1.7	3.7 vs 3.6	3.9 vs 1.7
	P 0.005	P<0.001		P 0.010		P<0.001
AI	4.0 vs 3.7	4.7 vs 4.0	3.2 vs 3.94	3.8 vs 3.7	4.1 vs 3.9	4.2 vs 3.7
	P 0.045
10 yr CV Risk	15.9 vs 17.9	13.5 vs 14.4	14 vs 15.7	10.1 vs 13.2	13.5 vs 14.1	11.2 vs 12.2
				P 0.009